Design and Refinement of CyberCell TM,a Virtual Reality Health Education Program for Adolescents and Young Adults with Sickle Cell Disease

Abstract

For people living with sickle cell disease (SCD), the risk for disease complications and premature death rises sharply in adolescence and young adulthood, when chronic organ damage is compounded by reduced preventive care. To make informed health care decisions, adolescents and young adults (AYAs) require effective education about their health condition and treatment options. We aimed to systematically design and develop a user-centered, evidence-based virtual reality (VR) health education program to optimize the use of SCD therapies among AYAs with SCD. We engaged a diverse team including AYAs with SCD and their caregivers, multidisciplinary SCD clinicians and researchers, patient education specialists, and health technology developers. Stakeholder meetings and codesign workshops were used to evaluate end-user and implementer needs, develop low- and high-fidelity prototypes of the VR program, and draft an implementation plan. Subsequently, iterative cycles of usability testing were conducted with 17 AYAs with SCD (M = 16.82 years, 59% male, 94% Black) and six SCD clinicians (83% female, 50% Black) to assess technical and functional reliability and to refine the implementation plan. Rapid assessment procedures were used to synthesize think-aloud field notes and qualitative interview data into a summary matrix of potential prototype modifications. Through these iterative, user-centered design processes, our team developed and refined CyberCell^TM, a VR health education program for AYAs with SCD. CyberCell provides immersive, interactive, and evidence-based education about SCD and treatment options, with the goal of facilitating deeper learning and increasing motivation for health behavior change. Think-aloud procedures revealed various challenges with wayfinding and interaction in early prototype versions, which were addressed to improve user experience. Interviews demonstrated satisfaction with CyberCell and potential positive impacts on patient–provider communication and patient health behaviors. Future research will evaluate the feasibility and effectiveness of CyberCell on enhancing the reach and uptake of disease-modifying therapies, thereby improving health for AYAs with SCD.

Sickle cell disease (SCD) is a group of genetic disorders resulting in rigid, abnormally adhesive, and dehydrated red blood cells. Individuals with SCD can experience severe complications, including anemia, pain, stroke, and organ injury,¹ which contribute to poor quality of life^2,3 and early mortality.¹ Risk for disease complications and premature death rises sharply in adolescence and young adulthood,^4,5 when chronic organ damage is compounded by inconsistent follow-up and reduced preventive care.^6,7

Safe and effective therapies are available for individuals with SCD, but pervasive research-to-practice gaps limit their reach. Hydroxyurea (HU) is the gold standard treatment for SCD.¹ It reduces complications,^8–15 health care utilization, and costs,^16,17 and it improves quality of life,¹⁸ growth,¹⁹ and survival.^20,21 Despite decades of strong evidence for HU,¹ uptake has been slow.^22,23 Recent data indicate that only about 25% of individuals with SCD are prescribed HU.²³ Suboptimal HU use is especially notable among adolescents and young adults (AYAs), who have the fewest days supplied, longest breaks, and poorest adherence of all age groups.^24–26 Barriers to HU utilization are multi-factorial.^27,28 AYAs report lack of involvement in decision-making, inadequate knowledge, and doubts about efficacy and safety.^29–33 Providers may not offer HU due to biased assumptions about patient adherence.^27,34 These challenges are compounded by structural and social determinants of health obstacles to care that are prevalent in this population (e.g., limited transportation, low health literacy).²⁷ Similar challenges limit the use of newer therapies that have been approved by the FDA in recent years (i.e., L-glutamine, crizanlizumab),^35–37 with current uptake estimated at <5% of the population.²³

To make informed health care decisions, AYAs require effective education about their health condition and available treatment options. Unfortunately, existing SCD education strategies are not user-centered, grounded in health promotion theory, or designed for dissemination.^38–40 For example, pharmacy handouts on HU rarely identify SCD as an indication for use, often contain inaccuracies related to long-term cancer risk, and have an average reading level two grades higher than recommended for patient education.⁴¹

Virtual reality (VR) is a promising approach to delivering health education for AYAs with SCD. Given the superiority of immersive, “learning-by-doing” approaches over traditional instruction,^42,43 VR is gaining momentum as a patient education tool in health care.⁴⁴ VR has demonstrated efficacy in improving health knowledge and promoting adoption of preventive behaviors in adult patients and caregivers.^45–49 Very few studies have used VR for patient education in pediatrics, demonstrating high satisfaction among youth undergoing chest radiography⁵⁰ and endoscopic procedures.⁵¹ However, VR-based instruction is widely employed in K-12 education, with strong evidence of enhancing knowledge and skills.⁵² As such, VR education represents a promising avenue for enhancing AYAs’ knowledge and motivation to use disease-modifying therapies best aligned with their values and preferences.

Guided by the Accelerated Creation-to-Sustainment (ACTS) model,⁵³ we aimed to systematically codesign, develop, and refine a user-centered, evidence-based VR health education program to optimize use of therapies among AYAs with SCD. The ACTS model outlines three stages to rapidly move from initial project conceptualization to a sustainable technology-enabled service: Create, Trial, and Sustainment.⁵³ This paper presents our efforts to complete the Create stage of the model, which focuses on employing user-centered design⁵⁴ to engage with key stakeholders in developing a minimally viable technology (i.e., functional, free of major usability issues, and safe) and implementation plan that is ready for first deployment and can be further optimized in the next stage. We also report on the acceptability and usability of the program and explore implementation barriers and facilitators.

Materials and Methods

Phase 1: Design and develop

Ethical considerations

All study procedures (Phases 1 and 2) were reviewed and approved by the Nemours Children’s Health Institutional Review Board (#1600953). No research participants were enrolled and no study data were collected during Phase 1, which involved codesign workshops and meetings with our stakeholder workgroup (i.e., members of the project team). This study is reported in accordance with guidance for reporting intervention development studies in health research (GUIDED).⁵⁵

Stakeholder workgroup

We assembled a diverse team including AYAs with SCD and their caregivers, multidisciplinary SCD clinicians and researchers, patient education specialists, and health technology developers. Most technology-enhanced interventions evaluated in clinical trials were developed with limited input from end users,⁵³ contributing to pervasive challenges with high attrition.⁵⁶ In contrast, we sought to involve end users (AYAs with SCD) and implementers (SCD health care providers) in every stage of intervention design and development to ensure that our VR prototype was relevant, appealing, practical, and intuitive. Stakeholders were also engaged in all aspects of study planning and execution to enhance alignment of this research with the priorities, preferences, and needs of end users.⁵⁷

Procedures

Consistent with the Create stage of the ACTS model,⁵³ we first focused on obtaining information from our stakeholder workgroup via bimonthly virtual meetings and two half-day codesign workshops (i.e., intensive ideation and design sessions) at Nemours Children’s Hospital Delaware (NCHD), with remote participation options for those who could not attend in-person. NCHD is a children’s hospital in the mid-Atlantic region of the United States. During initial meetings, we collaboratively brainstormed end-user and implementer needs and preferences for a VR health education program, linked those requirements to proposed VR prototype content and features, and created and obtained feedback on low-fidelity prototypes (e.g., storyboards, basic 3D models). These meetings informed the development of a higher-fidelity version, which stakeholders tested during the first codesign workshop. In addition to providing input on the VR prototype, stakeholders engaged in a free listing activity to generate ideas for additional content and features. Subsequent meetings involved further specification of more fully functioning, higher-fidelity prototypes. During the second codesign workshop, members of the stakeholder workgroup tested a high-fidelity version of the VR program and collaborated to draft an initial implementation plan including strategies, timeframe, milestones, and performance measures in preparation for a future trial.⁵⁸

CyberCell^TM: A sickle cell VR experience

Through these iterative, user-centered design processes, our team developed CyberCell, a VR health education program for AYAs with SCD. CyberCell provides immersive, interactive, and evidence-based education about SCD and treatment options, with the goal of facilitating deeper learning and increasing motivation for health behavior change. CyberCell enables users to visualize and interact with healthy and sickled red blood cells, observe health complications associated with sickling, and explore how disease-modifying therapies (i.e., HU and crizanlizumab) impact red blood cell functioning within a simulated three-dimensional blood vessel environment (see Fig. 1).

FIG. 1.

CyberCell: A sickle cell VR experience. Member of our stakeholder workgroup (young adult with SCD) using CyberCell (top right and bottom left) and snapshots of the user’s perspective within CyberCell (top left and bottom right). VR, virtual reality.

CyberCell content and features were informed by our prior research, which revealed that decisions about starting disease-modifying therapies are strongly shaped by patient knowledge and beliefs (e.g., understanding of how therapies work, perceived safety and efficacy of treatments, awareness of ongoing organ damage from untreated SCD).^30,59 In addition, AYAs desired education about SCD and treatment options that is engaging, easy to understand, and offered in multiple formats (e.g., written, audio, visual), underscoring the need to transform and improve how health education is delivered for this population. CyberCell is also guided by the Health Belief Model (HBM),⁶⁰ which posits that health behaviors (e.g., using a disease-modifying therapy) are influenced by perceived susceptibility and severity (e.g., of SCD-related complications) as well as perceived benefits (e.g., prevention or reduction of complications) and barriers (e.g., concerns about side effects). Educational programs informed by the HBM have demonstrated success in enhancing adoption of health behaviors.^61–65

Phase 2: Refine

Ethical considerations

Research team members contacted potential study participants (i.e., AYAs with SCD, hematology clinicians) via mail, phone, email, and/or during SCD clinic appointments at NCHD. Research team members explained the study to potential participants and reviewed the informed consent (and assent, for patients <18 years of age) documents in a private, quiet space in the hospital. Potential participants were encouraged to ask questions about the research and given time to decide about participating. Those who agreed to proceed with participating documented their consent/assent for the research project by signing the consent/assent form.

Procedures

Consistent with the ACTS model, we conducted a formal usability evaluation and intensive qualitative assessment to refine the VR prototype and implementation plan. Specifically, we recruited AYAs with SCD (ages 13–21 years) and hematology clinicians (who did not serve on our stakeholder workgroup) to participate in iterative cycles of usability testing to assess technical (i.e., software and hardware perform consistently) and functional reliability (i.e., users can perform the intended actions) and provide feedback on the draft implementation plan. Patients were contacted by mail, phone, email, and/or during a clinic appointment. Health care providers were contacted via email. Following assent/consent, usability testing sessions were conducted at NCHD. Participants used the VR prototype while “thinking aloud,” a well-established procedure to obtain in vivo feedback from end users.⁶⁶ Field notes were used to document any technical difficulties and observations on user engagement. Next, using a semi-structured interview, we assessed perspectives on the VR prototype (e.g., ease of use, clarity, acceptability, recommendations for improvement) and its implementation (e.g., preferences for strategies to integrate the VR program into clinical care). Usability testing sessions were audio- and screen-recorded and transcribed. Participants received $25.

Participants

Patients were recruited using maximum variation purposeful sampling⁶⁷ to ensure a diverse sample with regard to demographic and clinical characteristics (e.g., age, sex, socioeconomic status, disease severity) and extent of exposure to disease-modifying therapies. Youth were eligible to participate if they were: (a) of age 13–21 years, (b) diagnosed with SCD, and (c) receiving sickle cell care at NCHD. We also invited all NCHD providers who specialize in caring for youth with SCD to participate. English language fluency was a requirement for all participants. Youth and providers who reported history of seizures were excluded.

Measures

Demographic and clinical characteristics

Electronic health record review and a self-report survey were used to assess participant clinical and demographic characteristics.

Usability testing guides

Separate usability testing session guides were developed for patients and providers (see Supplementary Data). Participants were asked to use the VR prototype while verbalizing what they were thinking, looking at, doing, and feeling. The interview guide then prompted additional perspectives on the VR prototype (e.g., overall impressions, difficulties encountered, experience navigating the virtual environment) and implementation (e.g., ways to integrate the prototype into a typical clinic visit).

Data analysis

Participant demographic and clinical characteristics were summarized using descriptive statistics. Data analysis began once the first usability session was completed to inform real-time modifications to the VR prototype before subsequent testing cycles. Rapid assessment procedures (RAP)⁶⁸ were used to synthesize think-aloud field notes and qualitative interview data into a summary matrix of potential prototype modifications. RAP is a team-based, highly efficient qualitative analytic approach^68–70 that is commonly used in program planning and evaluation.^71,72 Following RAP analysis, data on usability challenges and acceptability were summarized into broader themes via team discussion. Qualitative data on future implementation of the VR program within clinical settings were organized into barriers and facilitators using the Consolidated Framework for Implementation Research (CFIR),⁷³ which synthesizes theories and empirical work on factors most likely to influence implementation of an innovation.

Results

In total, we contacted 26 AYAs with SCD and 8 health care providers who specialize in caring for youth with SCD to invite them to participate in Phase 2. One AYA declined, 8 were interested but did not enroll due to time constraints, and 17 AYAs consented and participated. Two health care providers did not respond to the study invitation email, and six providers consented and enrolled. Most AYAs identified as male (59%), non-Hispanic/Latinx (88%), and Black or African American (94%; see Table 1). Most health care providers were female (83%) and non-Hispanic/Latinx (100%). Health care providers identified as Black or African American (50%), White (33%), and multiracial (17%).

Table 1.

Participant Demographic Characteristics

Patient participants (N = 17)	Frequency (%)
Gender
Female	7 (41.2)
Male	10 (58.8)
Race
Black or African American	15 (88.2)
Multiracial (Black and White)	1 (5.9)
Not reported	1 (5.9)
Ethnicity
Hispanic or Latinx	2 (11.8)
Non-Hispanic or Latinx	14 (82.4)
Not reported	1 (5.9)
Sickle cell disease genotype
SS	15 (88.2)
SC	2 (11.8)
	M (SD), range
Age (years)	16.82 (2.56), 13–21
Health care provider participants (N = 6)	Frequency (%)
Gender
Female	5 (83.3)
Male	1 (16.7)
Race
Black or African American	3 (50.0)
White	2 (33.3)
Multiracial (Asian and White)	1 (16.7)
Ethnicity
Hispanic or Latinx	0 (0)
Non-Hispanic or Latinx	6 (100)
Discipline
Nurse practitioner	2 (33.4)
Physician	2 (33.4)
Psychologist	1 (16.7)
Social worker	1 (16.7)
	M (SD), range
Years in practice	13.92 (9.97), 5–30

Usability

Think-aloud procedures revealed difficulties related to wayfinding and navigation within the three-dimensional environment and completion of more complex, interactive user actions in early prototype versions. For instance, some users had difficulty understanding when and how to move forward through the experience, as well as how to interact with blood cells (e.g., the grabbing function). In addition, the VR experience was initially intended to be used by participants while standing, but some users preferred to sit or were unable to stand due to receiving treatments (e.g., blood transfusion) that required them to remain in a hospital bed. Modifications were made iteratively to address these challenges (see Fig. 2), including enhancements to the instructions users receive both before and during the VR experience, the addition of audio and visual wayfinding markers and navigational cues, simplifying 3D models, incorporating visual design elements such as color and contrast to aid in drawing user attention to directional cues, and enabling multiple options for viewing the VR environment (e.g., physically moving one’s head and body vs. use of the controller’s joystick). No adverse events were reported during usability testing of this VR experience.

FIG. 2.

Usability challenges and solutions. Usability issues that arose during think-aloud testing and corresponding solutions implemented.

Acceptability

Qualitative interviews revealed several themes related to acceptability of CyberCell: (1) CyberCell is an engaging, immersive, and interactive way to learn about SCD and treatment options; (2) deeper learning enhances AYAs’ motivation for health behavior change (i.e., medication initiation or adherence); and (3) AYAs with SCD and their health care providers report high satisfaction with VR as an approach to educating patients and facilitating communication between patients and providers (see Table 2 for illustrative quotes).

Table 2.

Acceptability Themes Identified and Illustrative Quotes

Theme	Illustrative quotes
CyberCell is an engaging, immersive, and interactive way to learn about SCD and treatment options	“It’s more in-depth because its hands-on. Instead of someone telling you, you really get to see what actually happens … You get a deeper understanding.” (20-year-old male with SCD)“Showing what happens inside the blood vessel is … because you can’t really see inside your blood vessel, so it’s really nice to see with your own eyes … Like, for criz for example. I didn’t know it made the blood cells bounce off [blood vessel walls].” (19-year-old male with SCD)“Not only does it give a nice overview of what the medicines do, but even bigger than that, it gives a beautiful picture of how sickle cell works inside the blood vessels. And I like that it shows not just the sickle cells clogging up, but it shows the vessel damage. It shows hemolysis and explains what that is. And it’s very simple.” (Pediatric Hematologist)
Deeper learning enhances motivation for health behavior change	“I did not know there was anything else to learn about sickle cell. I thought I knew everything. I learned what hydroxyurea does, that one was an enlightening revelation. I didn’t know hydroxyurea was that impressive … now I’ll take it seriously.” (20-year-old male with SCD)“…You don’t how it actually works, you’re just going based off what somebody’s telling you. So, seeing it—you get to see like, ‘Oh, this is how it’s benefitting me, maybe I should take it more, or learn about it more for myself.’ It’s just different when somebody’s just telling you versus you actually looking into it …. I feel like it’s important to take [hydroxyurea] more than I actually do.” (19-year-old female with SCD)“I think [CyberCell would help] if you’re talking to somebody for the first time about the medicines. I think if you’re trying to convince somebody that’s not compliant why they should be compliant. Somebody who was really little when they started a drug and maybe doesn’t know how it works, and you feel like they’re old enough to understand it [now].” (Pediatric Hematologist)
AYAs with SCD and their health care providers are highly satisfied with VR as an approach to educate patients and facilitate patient-provider communication	“It blew me away because I thought it would be just like, “Okay, we got new medicines for you to go through. That’s all you can do.” I didn’t think we was going to be able to actually interact with the cells. So, I was really, really excited about that part, and I think other people would like it, too … A lot of people don’t like learning, but [VR] makes it fun.” (18-year-old female with SCD)“[VR] is more fun for kids especially. We’re seeing information from doctors just talking. It is kind of boring. This is more entertaining.” (16-year-old female with SCD)“For patients and caregivers whose health literacy is not as high, it’s easier to really just listen to it and see it rather than having to read something.” (Pediatric Psychologist)

Theme 1: CyberCell is an engaging, immersive, and interactive way to learn about SCD and treatment options

Most AYAs and health care providers described high satisfaction with CyberCell as a health education program because of its emphasis on engagement, immersion, and interactivity. For example, a young adult commented:

“I liked that [CyberCell] gave you a different way to learn things. Because a lot of people don’t understand something because they’re more of a kinesthetic learner, and that’s as hands-on as you’re going to get … I learned about cell docking stations. And I learned that sickle cells aren’t just like cells that are sickle shaped. That they can go from whole to sickled to whole again.” (18-year-old female with SCD)

Similarly, a health care provider noted:

“It’s one thing to talk about sickle cells, but seeing the cells and then seeing what these medications actually do … just reaching out and touching things made it fun … it’s one thing to talk about vessels like it’s an abstract concept. Actually seeing [sickle cells] stuck together, to be able to provide that visual representation, is amazing.” (Pediatric Hematology Nurse Practitioner)

Theme 2: Deeper learning enhances AYAs’ motivation for health behavior change (i.e., medication initiation or adherence)

Participants also discussed that by facilitating enhanced understanding of SCD and treatment options, CyberCell may promote increased motivation for adaptive health behavior change among AYAs with SCD. For instance, when reflecting on her experience using CyberCell, an adolescent noted:

“When it talked about hydroxyurea, what it does and how it can help, it was interesting because I didn’t really know what it did. I take the medicine, but I didn’t really know what it did. It makes you want to take the medication because you see what it does with your own eyes.” (14-year-old female with SCD)

Theme 3: AYAs with SCD and their health care providers report high satisfaction with VR as an approach to educating patients and facilitating communication between patients and providers

Finally, AYAs with SCD and their health care providers described enthusiasm around the use of VR to deliver patient education and promote meaningful conversation between patients and providers. Considering how CyberCell compares to existing patient education approaches, one clinician reported:

“[VR] is more exciting and interactive and gives people choices… it allows them to take control about what they hear about. And, if they want to go back and look at something again, then they don’t have to worry about asking to repeat or circle back for clarification… If you’re talking about a new medicine or introducing a new therapy to somebody, [CyberCell] might be a way to help them understand why or what it does… We should think about it as a way to engage our patients and open a conversation.” (Lifespan Hematologist)

Implementation barriers and facilitators

Finally, qualitative interviews with AYAs and health care providers highlighted several potential facilitators and barriers to implementing CyberCell as a component of sickle cell care (see Table 3). Barriers and facilitators fell within two CFIR domains: (1) Innovation and (2) Inner Setting. With regard to CyberCell itself (i.e., the innovation), AYAs and health care providers identified several perceived advantages relative to existing patient education approaches (e.g., easier to understand and remember, more engaging and interactive). For instance, one young adult with SCD commented:

Table 3.

Implementation Barriers and Facilitators Identified and Illustrative Quotes

CFIR construct	Potential barriers and facilitators	Illustrative quotes
Domain: Innovation
Innovation relative advantage	Facilitator:CyberCell offers advantages over traditional patient education modalities	“You remember [CyberCell] more than you would a doctor talking. When a doctor gives a speech, it’s hard to understand. When you see something, it has a different effect… you remember a lot of the information.” (20-year-old male with SCD)“[Doctors] just talk to me. They’ll give me booklets and pamphlets. I’m going to be honest, I don’t think I ever read the pamphlets. The VR is more fun… [it is] a fun way to explore while also learning about sickle cell.” (18-year-old female with SCD)“[CyberCell] is a way to interpret or translate some of the things that clinicians talk about into language or concepts that might be more easily accessible to patients or help them learn in a way that’s different than just listening or reading… It’s more interactive and entertaining. And, I think it is probably a lower health literacy level or more approachable than what we as clinicians tend to say to people.” (Lifespan Hematologist)“[CyberCell] is just much more visual and much more fun for younger people. It gets them involved in it instead of just passive listening.” (Pediatric Hematologist)
Innovation Complexity	Barrier:Learning how to use and administer CyberCell can be complex	“I think you got to get past the point of learning what you’re doing… For someone that doesn’t [have experience using VR], I think you’ll spend more time trying to teach them what to do [when using CyberCell].” (Social Worker)“It might be helpful to just give people a quick minute or two to sort of test it out within the VR thing. Testing it out to see if they have any questions or difficulties before it starts. Maybe that could be helpful, a short test run. I think once that’s done, I think it’ll be fine for most people.” (Pediatric Psychologist)
CFIR Domain: Inner Setting
Compatibility	Facilitator:CyberCell is compatible with clinical workflows, systems, and processes	“It’s not too long, but it’s long enough.” (19-year-old male with SCD)“Before the doctor comes in say, ‘Hey, we did your weight, and now you’re waiting for the doctor. You have 15–20 minutes. You can [use CyberCell], and then talk to the doctor.’ And then, it may bring up questions to ask [the provider].” (Social Worker)“The best time [to use CyberCell] would be if patients were in the waiting room [or] if they’re here for those longer days, like hem/pulm or hem/optho [clinic], maybe in between seeing providers… We could [also] use it on the inpatient side [when] we’re giving them information about [a therapy that] we’re advocating for.” (Pediatric Hematology Nurse Practitioner)“[At] a check-up, the routine [could be]: you sit down, your doctor comes in and sits next to you, they give you a headset, and then they explain it. That would be great. That would be the perfect balance of these two elements…You don’t want to take away the human connection. You don’t want to just give me the headset and I sit here and watch and then go home.” (20-year-old male with SCD)
Compatibility	Barrier:CyberCell is not accessible to patients who do not speak English	“Certainly, people who don’t speak English wouldn’t be able to access it in its current form.” (Lifespan Hematologist)
Available Resources	Barrier:Resource constraints (i.e., time, staff) are likely challenges to using CyberCell in clinical settings	“The providers are moving from patient to patient and wanting to get through it. So, finding that time, when would they be able to do the VR? That will be the biggest barrier.” (Pediatric Hematology Nurse Practitioner)“Time, I don’t think would be a big barrier because again, it didn’t seem to take that much time. Although, I know our families are sometimes eager to just get the visit over with.” (Pediatric Psychologist)“Once it’s not a research thing, who would support it? That’s really—I don’t know. I would like to say that I’d be willing, but I just don’t know that I’d be able to all the time. I also don’t know that the other providers would, for different reasons. I wonder if it could be something that could be a volunteer role, but they’d have to be savvy with this kind of thing. Dang, we need more staff.” (Pediatric Hematology Nurse Practitioner)

CFIR, Consolidated Framework for Implementation Research.

“A lot of informational things, they’re usually very bland. You never really see something eye-catching. They’re usually just a pamphlet, something you flip through a couple times. This [CyberCell] is interactive… This is definitely one of the easiest ways – and interactive and fun ways – to get to learn about sickle cell… it’s really a game changer in explaining medicines and breaking down treatments. This is really a game changer.” (19-year-old male with SCD)

On the other hand, several clinicians described that the complexity of learning how to use CyberCell is an important barrier to implementation in busy clinical settings, with one noting:

“The learning curve [to administer CyberCell] is the biggest [barrier]. The younger population may be able to catch on to it quicker, but just getting through that part of it, as opposed to, it’s easy to talk to someone and hand out pamphlets… Initially, I’m like, ‘What am I taking in if I’m trying to figure out how to navigate the system? Am I learning anything, or am I just learning how to navigate the VR?’ Which is what I felt like my first couple minutes was, me learning the VR.” (Pediatric Hematology Nurse Practitioner)

Within the Inner Setting domain, participants discussed that CyberCell is compatible with existing clinical workflows, systems, and processes. For example, many participants noted that CyberCell is appropriate in length, with one pediatric hematologist commenting: “[The length was] perfect. Not too long, not too short.” Others described how CyberCell could be implemented across different clinical settings, including outpatient clinics, infusion centers, and inpatient hospital rooms:

“Before I get the blood drawn, I have some free time. Or, after I get finished talking to the doctor. [AYAs could use CyberCell] in here [infusion center] because you’ll have space to stand up and move around, it won’t be in anyone’s way.” (21-year-old male with SCD)

“When you’re admitted… whenever they’ve settled in, they have a bit of free time… when I was admitted, if I wasn’t in pain, I was pretty bored.” (18-year-old female with SCD)

However, one clinician noted an important compatibility barrier for clinics that serve individuals with SCD who do not speak English, in that CyberCell is currently available only in English. In addition, several health care providers noted resource constraints (i.e., time, staff) that may hinder use of CyberCell in clinical settings:

“Somebody actually has to take the time to set it up, put it on the person, and tell them how to do it, and stand there. If you are going to put it in a provider visit, that’s 15 minutes… [It may be] better to have somebody else other than the provider that’s doing the visit to [administer CyberCell] because I think you’re going to have trouble with provider time.” (Pediatric Hematologist)

Discussion

Overall, findings suggest high usability and acceptability of CyberCell among AYAs with SCD and their health care providers. Think-aloud testing revealed various challenges that were addressed to improve user experience. Qualitative interviews with patients and providers demonstrated satisfaction with VR as an approach to provide hands-on learning about SCD and treatment options, and potential benefits of this improved knowledge on patient–provider communication and patient health behaviors. Together, think-aloud procedures and interviews also provided key insights about implementation that will inform additional CyberCell modifications to facilitate future dissemination and sustainment of this VR health education program.

Our formative usability testing, comprised of think-aloud procedures and qualitative interviews, played a critical role in developing and refining CyberCell. Based on observations and feedback received during usability testing, we implemented various design changes to address challenges related to wayfinding and interaction between the user and elements of the virtual blood vessel environment. These changes were made iteratively, such that updated prototypes were tested on subsequent usability testing participants. While successful in identifying nearly all usability issues that users were likely to experience, this method required many rounds of prototype modification. In the future, it may be more efficient to batch observations and feedback from usability testing and perform a predetermined number of planned rounds of modification. In addition, the use of automated tools to obtain objective measures of usability (e.g., head, hand, or eye tracking, speed of task performance)⁷⁴ might supplement the subjective data obtained through think-aloud procedures and interviews.

While we did not formally evaluate the impact of CyberCell on knowledge or behavior in this usability study, our qualitative data are consistent with a recent meta-analysis, which found that immersive VR learning approaches are more effective for both knowledge and skill development than nonimmersive approaches, especially for children and adolescents and in the area of science education.⁴² Our findings are also consistent with research demonstrating that digital health technologies (broadly defined) that support disease self-management are highly acceptable among individuals with SCD.⁷⁵ Importantly, our study also adds to a small yet growing body of evidence supporting the role of VR in improving health education and healthy behaviors among individuals with chronic illness.⁷⁶

Several aspects of CyberCell were identified as helpful for future large-scale dissemination. Prior work suggests that health care providers are more likely to adopt VR in clinical practice when there is clear value added by this technology.⁷⁷ In this study, both patients and providers noted that CyberCell is an effective way to engage AYAs in their care and facilitate patient–provider communication. They also reported that CyberCell explains complex medical information in a way that is easily understood by AYAs. The program was flexible enough to be implemented across clinical settings (e.g., outpatient clinic, infusion center, inpatient hospital room). While patients and providers found CyberCell appropriate in length, time constraints in busy clinical settings where youth with SCD receive care were identified as a potential barrier. In addition, participants noted that superusers or in-experience tutorials may be needed to assist patients with less prior exposure to or self-efficacy with using VR. These findings align with existing research, with a recent scoping review highlighting that insufficient practical resources including time, technical support, equipment, and physical space are frequently identified barriers to implementation of VR in health care.⁷⁷ To improve ease of deployment, we are building an in-experience tutorial (i.e., instructions for how to use CyberCell and demo space to practice skills). We also plan to explore opportunities to translate CyberCell into other languages, deploy remote synchronized VR experiences between multiple users (e.g., patient and caregivers or providers), and distribute content to devices remotely to improve accessibility, implementation, and broad dissemination.

Several limitations should be noted and considered. This study was conducted at a single pediatric SCD center, and thus, findings may not generalize to all settings in which AYAs with SCD receive care within the United States and globally. While the evaluation of feasibility and effectiveness was outside of the scope of this study, these data will be important to collect in future research. Future work will also explore additional content for patients, adaptations for other users (e.g., caregivers, health care trainees, and providers), language and cultural adaptation, and investigation of methods to support scaling and spreading this program to the broader sickle cell community.

This study supports the use of VR to provide engaging and interactive education to AYAs with SCD about their condition and treatment options. We are currently conducting a pilot pragmatic trial to evaluate the feasibility and preliminary effectiveness of CyberCell as one component of a broader shared decision-making toolkit for AYAs with SCD. Ultimately, we aim to produce a user-centered, acceptable, feasible, effective, and sustainable VR experience that can facilitate education, empowerment, and self-management among AYAs living with SCD.

Footnotes

Acknowledgments

The authors sincerely appreciate the AYAs with SCD, caregivers of individuals with SCD, clinicians, and community organization leaders who contributed to this program and the study at large. The authors also thank Allie Alvarado, Scott Shaw, Dr. Maricar Diaz, Dr. Roger Acevedo, and the students in the Sam Houston State University XR Lab for Health and Humanities.

Authors’ Contributions

A.K.H.: Conceptualization, methodology, validation, formal analysis, investigation, resources, data curation, writing—original draft, writing—review and editing, supervision, project administration, and funding acquisition. M.P.: Conceptualization, methodology, resources, writing—original draft, writing—review and editing, visualization, and supervision. B.B.: Validation, formal analysis, investigation, resources, data curation, writing—review and editing, supervision, and project administration. C.L.S.: Conceptualization, methodology, resources, and writing—review and editing. S.F.: Methodology, software, validation, investigation, resources, writing—review and editing, and supervision. D.M.: Conceptualization, resources, and writing—review and editing. S.H.: Resources, and writing—review and editing. A.D.: Validation, formal analysis, investigation, data curation, and writing—review and editing. M.A.A.: Conceptualization, methodology, resources, and writing—review and editing. L.E.C.: Methodology and writing—review and editing. F.F.: Conceptualization, methodology, software, validation, investigation, resources, writing—original draft, writing—review and editing, visualization, and supervision.

Author Disclosure Statement

M.P. and F.F. are co-founders of OnXR, Inc., an immersive technology company that provides technological support for CyberCell.

Funding Information

Funding for this work was provided by the Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders at Nemours Children’s Health (previously the Nemours Center for Cancer and Blood Disorders; PI: Hildenbrand) and the Patrick and Catherine Weldon Donaghue Medical Research Foundation (2022 Greater Value Portfolio, PI: Hildenbrand).

Supplementary Material

Abbreviations Used

References

National Heart Lung and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report. National Heart, Lung, and Blood Institute, US Department of Health and Human Services: Bethesda, MD; 2014.

Panepinto

, Bonner

. Health-related quality of life in sickle cell disease: Past, present, and future. Pediatr Blood Cancer, 2012; 59(2):377–385.

McClish

, Penberthy

, Bovbjerg

, et al. Health related quality of life in sickle cell patients: The PiSCES project. Health Qual Life Outcomes, 2005; 3:50–56; doi: 10.1186/1477-7525-3-50

Quinn

, Rogers

, McCavit

, et al. Improved survival of children and adolescents with sickle cell disease. Blood, 2010; 115(17):3447–3452; doi: 10.1182/blood-2009-07-233700

Hamideh

, Alvarez

. Sickle cell disease related mortality in the United States (1999–2009). Pediatr Blood Cancer, 2013; 60(9):1482–1486; doi: 10.1002/pbc.24557

Jordan

, Swerdlow

, Coates

. Systematic review of transition from adolescent to adult care in patients with sickle cell disease. J Pediatr Hematol Oncol, 2013; 35(3):165–169.

Crosby

, Quinn

, Kalinyak

. A biopsychosocial model for the management of patients with sickle-cell disease transitioning to adult medical care. Adv Ther, 2015; 32(4):293–305; doi: 10.1007/s12325-015-0197-1

Kinney

, Helms

, O’Branski

, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood, 1999; 94(5):1550–1554.

Wang

, Wynn

, Rogers

, et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr, 2001; 139(6):790–796; doi: 10.1067/mpd.2001.119590

10.

Wang

, Ware

, Miller

, et al.; BABY HUG investigators. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet, 2011; 377(9778):1663–1672; doi: 10.1016/S0140-6736(11)60355-3

11.

Zimmerman

, Schultz

, Davis

, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood, 2004; 103(6):2039–2045; doi: 10.1182/blood-2003-07-2475

12.

Ballas

, McCarthy

, Guo

, et al.; Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc, 2009; 101(10):1046–1051.

13.

Flanagan

, Howard

, Mortier

, et al. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res, 2010; 698(1–2):38–42; doi: 10.1016/j.mrgentox.2010.03.001

14.

McGann

, Howard

, Flanagan

, et al. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol, 2011; 154(1):134–140; doi: 10.1111/j.1365-2141.2011.08698.x

15.

Strouse

, Lanzkron

, Beach

, et al. Hydroxyurea for sickle cell disease: A systematic review for efficacy and toxicity in children. Pediatrics, 2008; 122(6):1332–1342; doi: 10.1542/peds.2008-0441

16.

Stallworth

, Jerrell

, Tripathi

. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. Am J Hematol, 2010; 85(10):795–797; doi: 10.1002/ajh.21772

17.

Wang

, Oyeku

, Luo

, et al.; BABY HUG Investigators. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics, 2013; 132(4):677–683; doi: 10.1542/peds.2013-0333

18.

Thornburg

, Calatroni

, Panepinto

. Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr Hematol Oncol, 2011; 33(4):251–254; doi: 10.1097/MPH.0b013e3182114c54

19.

Hankins

, Ware

, Rogers

, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study. Blood, 2005; 106(7):2269–2275; doi: 10.1182/Blood-2004-12-4973

20.

, Gulbis

, Dedeken

, et al. Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment. Pediatr Blood Cancer, 2015; 62(11):1956–1961; doi: 10.1002/pbc.25608

21.

Lobo

, Pinto

, Nascimento

, et al. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol, 2013; 161(6):852–860; doi: 10.1111/bjh.12323

22.

Okam

, Shaykevich

, Ebert

, et al. National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998–2008. Med Care, 2014; 52(7):612–618; doi: 10.1097/MLR.0000000000000143

23.

Newman

, Yang

, Suh

, et al. Use of disease-modifying treatments in patients with sickle cell disease. JAMA Netw Open, 2023; 6(11):e2344546; doi: 10.1001/jamanetworkopen.2023.44546

24.

Crego

, Douglas

, Bonnabeau

, et al. Sickle-Cell disease co-management, health care utilization, and hydroxyurea use. J Am Board Fam Med, 2020; 33(1):91–105; doi: 10.3122/jabfm.2020.01.190143

25.

Blinder

, Vekeman

, Sasane

, et al. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer, 2013; 60(5):828–835; doi: 10.1002/pbc.24459

26.

Mathias

, Nolan

, Klesges

, et al. Hydroxyurea use after transitions of care among young adults with sickle cell disease and Tennessee Medicaid Insurance. JAMA Netw Open, 2021; 4(10):e2128971; doi: 10.1001/jamanetworkopen.2021.28971

27.

Brandow

, Jirovec

, Panepinto

. Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilization. Am J Hematol, 2010; 85(8):611–613; doi: 10.1002/ajh.21749

28.

Brandow

, Panepinto

. Hydroxyurea use in sickle cell disease: The battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev Hematol, 2010; 3(3):255–260; doi: 10.1586/ehm.10.22

29.

Sinha

, Bakshi

, Ross

, et al. From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea. PLoS One, 2018; 13(6):e0199375; doi: 10.1371/journal.pone.0199375

30.

Hildenbrand

, Schultz

, Crosby

, et al. Youth and caregiver perspectives on barriers and facilitators to hydroxyurea uptake in pediatric sickle cell disease. Sickle Cell Disease Association of America 47th Annual National Convention. Baltimore, MD; 2019.

31.

Badawy

, Thompson

, Liem

. Beliefs about hydroxyurea in youth with sickle cell disease. Hematol Oncol Stem Cell Ther, 2018; 11(3):142–148; doi: 10.1016/j.hemonc.2018.01.001

32.

Badawy

, Thompson

, Penedo

, et al. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease. Eur J Haematol, 2017; 98(6):608–614; doi: 10.1111/ejh.12878

33.

Badawy

, Thompson

, Lai

J-S

, et al. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer, 2017; 64(6):e26369; doi: 10.1002/pbc.26369

34.

Pizzo

, Porter

, Carroll

, et al. Provider prescription of hydroxyurea in youth and adults with sickle cell disease: A review of prescription barriers and facilitators. Br J Haematol, 2023; 203(5):712–721; doi: 10.1111/bjh.19099

35.

Ding

, Bear

, Sood

, et al. Disease-modifying therapies for sickle cell disease: Decisional needs and supports among adolescents and young adults. Pediatr Blood Cancer, 2024; 71(7):e30999; doi: 10.1002/pbc.30999

36.

Hildenbrand

, Bear

, Alderfer

, et al. Healthcare provider perspectives on barriers to use of novel disease-modifying therapies among individuals with sickle cell disease. 50th Annual Sickle Cell Disease Association of America National Convention. Virtual; 2022.

37.

Sharma

, Young

, Carroll

, et al. Gene therapy in sickle cell disease: Attitudes and informational needs of patients and caregivers. Pediatr Blood Cancer, 2023; 70(6):e30319; doi: 10.1002/pbc.30319

38.

McClure

, Ng

, Vitzthum

, et al. A mismatch between patient education materials about sickle cell disease and the literacy level of their intended audience. Prev Chronic Dis, 2016; 13:E64; doi: 10.5888/pcd13.150478

39.

Pecker

, Kappa

, Greenfest

, et al. Targeted hydroxyurea education after an emergency department visit increases hydroxyurea use in children with sickle cell anemia. J Pediatr, 2018; 201:221–228.e16; doi: 10.1016/j.jpeds.2018.05.019

40.

LaVista

, Treise

, Dunbar

, et al. Development and evaluation of a patient empowerment video to promote hydroxyurea adoption in sickle cell disease. J Natl Med Assoc, 2009; 101(3):251–257; doi: 10.1016/s0027-9684(15)30853-1

41.

Cervi

, Diamantouros

, Azzam

, et al. Pharmacy hydroxyurea education materials for patients with sickle cell disease: An environmental scan and assessment of accuracy. Pediatr Blood Cancer, 2020; 67(5):e28179; doi: 10.1002/pbc.28179

42.

, Yu

, Gu

. Effectiveness of immersive virtual reality using head-mounted displays on learning performance: A meta-analysis. Brit J Educational Tech, 2020; 51(6):1991–2005; doi: 10.1111/bjet.13023

43.

Makransky

, Petersen

. The Cognitive Affective Model of Immersive Learning (CAMIL): A theoretical research-based model of learning in immersive virtual reality. Educ Psychol Rev, 2021; 33(3):937–958; doi: 10.1007/s10648-020-09586-2

44.

van der Kruk

, Zielinski

, MacDougall

, et al. Virtual reality as a patient education tool in healthcare: A scoping review. Patient Educ Couns, 2022; 105(7):1928–1942; doi: 10.1016/j.pec.2022.02.005

45.

Pandrangi

, Gaston

, Appelbaum

, et al. The application of virtual reality in patient education. Ann Vasc Surg, 2019; 59:184–189; doi: 10.1016/j.avsg.2019.01.015

46.

Jimenez

, Cumming

, Wang

, et al. Patient education using virtual reality increases knowledge and positive experience for breast cancer patients undergoing radiation therapy. Support Care Cancer, 2018; 26(8):2879–2888; doi: 10.1007/s00520-018-4114-4

47.

Thompson-Butel

, Shiner

, McGhee

, et al. The role of personalized virtual reality in education for patients post stroke-A qualitative case series. J Stroke Cerebrovasc Dis, 2019; 28(2):450–457; doi: 10.1016/j.jstrokecerebrovasdis.2018.10.018

48.

Ernstoff

, Cuervo

, Carneiro

, et al. Breaking down barriers: Using virtual reality to enhance patient education and improve colorectal cancer screening: 254. American J Gastroenterol, 2018; 113(Supplement):S146.

49.

Saab

, Landers

, Cooke

, et al. Enhancing men’s awareness of testicular disorders using a virtual reality intervention: A pre-post pilot study. Nurs Res, 2018; 67(5):349–358; doi: 10.1097/NNR.0000000000000303

50.

Han

S-H

, Park

J-W

, Choi

, et al. Effect of immersive virtual reality education before chest radiography on anxiety and distress among pediatric patients: A randomized clinical trial. JAMA Pediatr, 2019; 173(11):1026–1031; doi: 10.1001/jamapediatrics.2019.3000

51.

Palanica

, Leier

, Lee

, et al. Enhancing the patient experience for individuals undergoing endoscopic procedures using virtual reality. J Pediatr Gastroenterol Nutr, 2020; 70(3):341–343; doi: 10.1097/MPG.0000000000002577

52.

Merchant

, Goetz

, Cifuentes

, et al. Effectiveness of virtual reality-based instruction on students’ learning outcomes in K-12 and higher education: A meta-analysis. Computers & Education, 2014; 70:29–40; doi: 10.1016/j.compedu.2013.07.033

53.

Mohr

, Lyon

, Lattie

, et al. Accelerating digital mental health research from early design and creation to successful implementation and sustainment. J Med Internet Res, 2017; 19(5):e153; doi: 10.2196/jmir.7725

54.

Abras

, Maloney-Krichmar

, Preece

. User-Centered Design. In: Bainbridge

. (ed) Encyclopedia of Human-Computer Interaction. Sage: Thousand Oaks, CA; 2004, pp. 445–456.

55.

Duncan

, O’Cathain

, Rousseau

, et al. Guidance for reporting intervention development studies in health research (GUIDED): An evidence-based consensus study. BMJ Open, 2020; 10(4):e033516; doi: 10.1136/bmjopen-2019-033516

56.

Kelders

, Kok

, Ossebaard

, et al. Persuasive system design does matter: A systematic review of adherence to web-based interventions. J Med Internet Res, 2012; 14(6):e152; doi: 10.2196/jmir.2104

57.

Forsythe

, Carman

, Szydlowski

, et al. Patient engagement in research: Early findings from the patient-centered outcomes research institute. Health Aff (Millwood), 2019; 38(3):359–367; doi: 10.1377/hlthaff.2018.05067

58.

Powell

, Waltz

, Chinman

, et al. A refined compilation of implementation strategies: Results from the Expert Recommendations for Implementing Change (ERIC) project. Implement Sci, 2015; 10:21; doi: 10.1186/s13012-015-0209-1

59.

Hildenbrand

, Bear

, Schultz

, et al. Multidisciplinary healthcare provider perspectives on barriers and facilitators to hydroxyurea uptake among youth with sickle cell disease. Society of Pediatric Psychology Annual Conference. Dallas, TX; 2020.

60.

Strecher

, Rosenstock

. The health belief model. In: Baum

, Newman

, Weinman

, et al. (eds) Cambridge Handbook of Psychology, Health, and Medicine. Cambridge, UK: Cambridge University Press, 1997, pp.113–117.

61.

McVay

, Yancy

Jr , Bennett

, et al. A web-based intervention to increase weight loss treatment initiation: Results of a cluster randomized feasibility and acceptability trial. Transl Behav Med, 2021; 11(1):226–235; doi: 10.1093/tbm/ibz143

62.

Zare

, Ghodsbin

, Jahanbin

, et al. The effect of health belief model-based education on knowledge and prostate cancer screening behaviors: A randomized controlled trial. Int J Community Based Nurs Midwifery, 2016; 4(1):57–68.

63.

Naghashpour

, Shakerinejad

, Lourizadeh

, et al. Nutrition education based on health belief model improves dietary calcium intake among female students of junior high schools. J Health Popul Nutr, 2014; 32:420–429.

64.

Araban

, Baharzadeh

, Karimy

. Nutrition modification aimed at enhancing dietary iron and folic acid intake: An application of health belief model in practice. Eur J Public Health, 2017; 27(2):287–292; doi: 10.1093/eurpub/ckw238

65.

Jones

, Smith

, Llewellyn

. Evaluating the effectiveness of health belief model interventions in improving adherence: A systematic review. Health Psychol Rev, 2014; 8(3):253–269; doi: 10.1080/17437199.2013.802623

66.

Jaspers

MWM

. A comparison of usability methods for testing interactive health technologies: Methodological aspects and empirical evidence. Int J Med Inform, 2009; 78(5):340–353; doi: 10.1016/j.ijmedinf.2008.10.002

67.

Patton

. Qualitative Research & Evaluative Methods, 3rd ed. Sage Publications, Inc: Thousand Oaks, CA; 2002.

68.

Beebe

. Rapid Assessment Process: An Introduction. Altamira Press: Walnut Creek, CA; 2001.

69.

Utarini

, Winkvist

, Pelto

. Appraising studies in health using rapid assessment procedures (RAP): Eleven critical criteria. Human Organization, 2001; 60(4):390–400.

70.

Renfro

, Rome

, Gatwood

, et al. Use of Rapid Assessment Procedures when analyzing qualitative data in pharmacy research. Res Social Adm Pharm, 2022; 18(1):2249–2253; doi: 10.1016/j.sapharm.2021.05.013

71.

Cifuentes

, Alamo

, Kendall

, et al. Rapid assessment procedures in environmental sanitation research: A case study from the northern border of Mexico. Can J Public Health, 2006; 97(1):24–28.

72.

Scrimshaw

, Carballo

, Ramos

, et al. The AIDS rapid anthropological assessment procedures: A tool for health education planning and evaluation. Health Educ Q, 1991; 18(1):111–123.

73.

Damschroder

, Reardon

, Widerquist

MAO

, et al. The updated Consolidated Framework for Implementation Research based on user feedback. Implement Sci, 2022; 17(1):75; doi: 10.1186/s13012-022-01245-0

74.

Kamińska

, Zwoliński

, Laska-Leśniewicz

. Usability testing of virtual reality applications-The pilot study. Sensors (Basel, Switzerland), 2022; 22(4):1342; doi: 10.3390/s22041342

75.

Badawy

, Cronin

, Hankins

, et al. Patient-Centered eHealth interventions for children, adolescents, and adults with sickle cell disease: Systematic review. J Med Internet Res, 2018; 20(7):e10940; doi: 10.2196/10940

76.

Kuwabara

, Su

, Krauss

. Utilizing digital health technologies for patient education in lifestyle medicine. Am J Lifestyle Med, 2020; 14(2):137–142; doi: 10.1177/1559827619892547

77.

Kouijzer

MMTE

, Kip

, Bouman

YHA

, et al. Implementation of virtual reality in healthcare: A scoping review on the implementation process of virtual reality in various healthcare settings. Implement Sci Commun, 2023; 4(1):67; doi: 10.1186/s43058-023-00442-2

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB

Design and Refinement of CyberCell TM,a Virtual Reality Health Education Program for Adolescents and Young Adults with Sickle Cell Disease

Abstract

Materials and Methods

Phase 1: Design and develop

Ethical considerations

Stakeholder workgroup

Procedures

CyberCellTM: A sickle cell VR experience

Phase 2: Refine

Ethical considerations

Procedures

Participants

Measures

Demographic and clinical characteristics

Usability testing guides

Data analysis

Results

Usability

Acceptability

Theme 1: CyberCell is an engaging, immersive, and interactive way to learn about SCD and treatment options

Theme 2: Deeper learning enhances AYAs’ motivation for health behavior change (i.e., medication initiation or adherence)

Theme 3: AYAs with SCD and their health care providers report high satisfaction with VR as an approach to educating patients and facilitating communication between patients and providers

Implementation barriers and facilitators

Discussion

Footnotes

Acknowledgments

Authors’ Contributions

Author Disclosure Statement

Funding Information

Supplementary Material

Abbreviations Used

References

Supplementary Material

CyberCell^TM: A sickle cell VR experience